Holen Sie sich die Stockscreener-App
5.53
2.41%
0.13
Schlusskurs vom Vortag:
$5.40
Offen:
$5.4
24-Stunden-Volumen:
2.99M
Relative Volume:
1.18
Marktkapitalisierung:
$485.94M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-209.47M
KGV:
-1.6617
EPS:
-3.3279
Netto-Cashflow:
$-147.13M
1W Leistung:
+22.89%
1M Leistung:
+47.07%
6M Leistung:
-29.01%
1J Leistung:
+16.67%
1-Tages-Spanne:
$5.0595
$5.57
1-Wochen-Bereich:
$4.30
$5.57
52-Wochen-Spanne:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.53 | 485.94M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-02-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM) - Stock Titan
Verastem Inc outlines oncology focus as investors weigh long-term prospects - ad-hoc-news.de
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating - marketscreener.com
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkey
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
(VSTM) Volatility Zones as Tactical Triggers - Stock Traders Daily
VSTM Maintained by BTIG -- Price Target Unchanged at $18.00 - GuruFocus
Verastem Is Maintained at Buy by BTIG - Moomoo
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem, Inc. Stock Hits New 52-Week Low at $3.43 - MarketsMojo
Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM) - TradingView
Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
VSTM Forecast — Price Target — Prediction for 2027 - TradingView
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Price to book forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) insider sale notice: 21,492 shares reported for resale - Stock Titan
Verastem, Inc. Actuals & Estimates (GETTEX:2VSA) - TradingView
Enterprise value to revenue forward of Verastem, Inc. – GETTEX:2VSA - TradingView
2VSA Forecast — Price Target — Prediction for 2027 - TradingView
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Insider Monkey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Price to sales forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Price to book forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Verastem | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares - GuruFocus
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18.00 - GuruFocus
Verastem CFO Daniel Calkins sells $17,089 in company stock By Investing.com - Investing.com Nigeria
Form 4 Verastem Inc For: 24 June By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares - Investing.com UK
Verastem CFO Daniel Calkins sells $17,089 in company stock - Investing.com
Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding - Stock Titan
Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes - Stock Titan
VSTM Q1 2026 Earnings: EPS Beats Estimates by 2.19% as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
VSTM Reiterates by BTIG -- Price Target Maintained at $18.00 - GuruFocus
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential - Investing.com
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $8 to $18 - Moomoo
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated CancersSlideshow (NASDAQ:VSTM) 2026-06-24 - Seeking Alpha
H.C. Wainwright reiterates Verastem stock rating on drug trial data By Investing.com - Investing.com UK
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):